摘要
目的研究微小RNA-21(miR-21)在弥漫大B细胞淋巴瘤(DLBCL)中的表达,探讨miR-21表达与DLBCL发生、发展的意义及其与临床病理特征和预后的关系。方法采用实时荧光定量聚合酶链反应(RT—PCR)检测50例DLBCL存档蜡块和12例正常淋巴结中miR-21的表达,并采用免疫组织化学EnVision法检测bcl-2、p53在DLBCL中的表达。结果miR-21在DLBCL中高表达,且在非生发中心B细胞样(non—GCB)亚型中高于GCB亚型,50例DLBCL中有18例(36.0%)表达bcl-2,21例(42.0%)表达p53。DLBCL中miR-21表达水平与bcl-2呈负相关(P=0.020),与p53表达、DLBCL临床分期呈正相关(P=0.022;P=0.005),miR-21高表达的DLBCL患者3年生存率较miR-21低表达者低。结论miR-21高表达可能是DLBCL恶性度高的标志,是促进DLBCL肿瘤细胞增殖的重要因素,可能对预后有一定的指导意义。bcl-2、p53可能是miR-21在DLBcL中发挥作用的靶标。
Objective To investigate the expression of miR-21 in diffuse large B cell lymphoma (DLBCL) and normal lymph tissues and its potential relevance with clinicopathological characteristics. Methods The expression levels of miR-21 in 50 primary DLBCL and 12 normal lymph node tissue specimens were examined by TaqMan real-time polymerase chain reaction.The expression of bcl-2 and p53 was detected by immunohistochemistry staining. Results The expression of miR-21 was significantly higher in tumor tissues than that in normal tissues, in GCB subtypes higher than in non-GCB subtypes. And it was negatively correlated with bcl-2 (P=O.020), while positively correlated with p53 (P=0.022). Up-regulated miR-21 expression was low in three years of survival rate. Conclusion MiR-21 may indicate a more aggressive phenotype and serve as a molecular prognostic marker in DLBCL. High-expression of miR-21 is a key feature that is correlated with cell proliferation in DLBCL. miR-21 may have some guiding significance in prognosis, bcl-2, p53 is possibly one of the targets of miR-21 in DLBCL.
出处
《白血病.淋巴瘤》
CAS
2012年第5期269-272,共4页
Journal of Leukemia & Lymphoma